• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Signal Transduct Target Ther . A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2

tetano

Editor, Senior Moderator
Signal Transduct Target Ther


. 2024 Nov 6;9(1):301.
doi: 10.1038/s41392-024-02007-8. A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2

Ran An[SUP] #[/SUP][SUP] 1 [/SUP], Hao Yang[SUP] #[/SUP][SUP] 1 [/SUP], Cong Tang[SUP] #[/SUP][SUP] 1 [/SUP], Qianqian Li[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Qing Huang[SUP] #[/SUP][SUP] 1 [/SUP], Haixuan Wang[SUP] 1 [/SUP], Junbin Wang[SUP] 1 [/SUP], Yanan Zhou[SUP] 1 [/SUP], Yun Yang[SUP] 1 [/SUP], Hongyu Chen[SUP] 1 [/SUP], Wenhai Yu[SUP] 1 [/SUP], Bai Li[SUP] 1 [/SUP], Daoju Wu[SUP] 1 [/SUP], Yong Zhang[SUP] 1 [/SUP], Fangyu Luo[SUP] 1 [/SUP], Wenqi Quan[SUP] 1 [/SUP], Jingwen Xu[SUP] 1 [/SUP], Dongdong Lin[SUP] 1 [/SUP], Xiaoming Liang[SUP] 1 [/SUP], Yuhuan Yan[SUP] 1 [/SUP], Longhai Yuan[SUP] 1 [/SUP], Xuena Du[SUP] 1 [/SUP], Yuxia Yuan[SUP] 1 [/SUP], Yanwen Li[SUP] 1 [/SUP], Qiangming Sun[SUP] 4 5 6 7 [/SUP], Youchun Wang[SUP] 8 9 10 [/SUP], Shuaiyao Lu[SUP] 11 12 13 14 [/SUP]



Affiliations
Abstract

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge and evade immunity, resulting in breakthrough infections in vaccinated populations. There is an urgent need for the development of vaccines with broad protective effects. In this study, we selected hotspot mutations in the receptor-binding domain (RBD) that contribute to immune escape properties and integrated them into the original RBD protein to obtain a complex RBD protein (cRBD), and we found cRBDs have broad protective effects against SARS-CoV-2 variants. Three cRBDs were designed in our study. Compared with the BA.1 RBD protein, the cRBDs induced the production of higher levels of broader-spectrum neutralizing antibodies, suggesting stronger and broader protective efficacy. In viral challenge experiments, cRBDs were more effective than BA.1 RBD in attenuating lung pathologic injury. Among the three constructs, cRBD3 showed optimal broad-spectrum and protective effects and is a promising candidate for a broad-spectrum SARS-CoV-2 vaccine. In conclusion, immunization with cRBDs triggered immunity against a wide range of variants, including those that emerged after we had completed designing the cRBDs. This study preliminarily explores and validates the feasibility of incorporating hotspot mutations that contribute to immune evasion into the RBD to expand the activity spectrum of antigen-induced antibodies.


 
Back
Top Bottom